tiprankstipranks
Trending News
More News >

Akebia announces CHMP positive opinion for XOANACYL

Akebia (AKBA) Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the European Commission to approve XOANACYL for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease. Averoa, a renal-focused biopharmaceutical company, licensed the rights to develop and commercialize ferric citrate from Akebia in the European Economic Area and certain countries in Europe and the Middle East. The EC will review the CHMP recommendation, and a final decision is expected in approximately two months.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1